Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSPB1 | P04792 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28077125 | 0.87 | ALDH1A1 (0.54) | L3MBTL1SMN1; SMN2HSPB1MAPTALDH1A1 | |
| SCHEMBL27479660 | 0.87 | HSPB1 (0.53) | L3MBTL1HSPB1MAPTALDH1A1ATM | |
| SCHEMBL28406748 | 0.85 | HSPB1 (0.50) | L3MBTL1HSPB1MAPTATMTDP1 | |
| SCHEMBL2012345 | 0.84 | L3MBTL1 (0.52) | L3MBTL1HSPB1MAPTALDH1A1ATM | |
| SCHEMBL27719773 | 0.83 | L3MBTL1 (0.48) | L3MBTL1HSPB1MAPTALDH1A1ATM | |
| SCHEMBL823705 | 0.82 | RECQL (0.56) | SMN1; SMN2HSPB1MAPTALDH1A1TDP1 | |
| SCHEMBL30318004 | 0.82 | RECQL (0.56) | SMN1; SMN2HSPB1MAPTALDH1A1TDP1 | |
| SCHEMBL27662020 | 0.81 | L3MBTL1 (0.49) | L3MBTL1HSPB1MAPTALDH1A1ATM | |
| SCHEMBL1068743 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTALDH1A1MITFGAA | |
| SCHEMBL6742909 | 0.81 | ALDH1A1 (0.53) | L3MBTL1SMN1; SMN2MAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101321736-B | To M1Compounds with receptor activity and their use in medicine | GLAXO GROUP LTD | 2012-04-04 | — | — | CN | disclosed |
| US-7517899-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-04-14 | — | — | US | disclosed |
| CN-101321736-A | To M1Compounds with receptor activity and their use in medicine | GLAXO GROUP LTD (GB) | 2008-12-10 | — | — | CN | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| CN-1318403-C | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-05-30 | — | — | CN | disclosed |
| CN-1960973-A | 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine(NE) and the serotonine(5-HT) activity and the monoamine reuptake | WYETH CORP (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1732887-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth (US) | 2006-12-20 | — | — | EP | disclosed |
| CN-1250526-C | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN INC (US) | 2006-04-12 | — | — | CN | disclosed |
| WO-2005097744-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
| CN-1668589-A | Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-14 | — | — | CN | disclosed |
| CN-1311775-A | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN INC (US) | 2001-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | L3MBTL1 4659/4885SMN1; SMN2 184/4885HSPB1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.